Michelson Medical Research Foundation Inc.

The Michelson Medical Research Foundation (MMRF) operates primarily as a private family foundation channeling resources through Dr. Gary K. Michelson's interconnected philanthropic ecosystem. Understanding this architecture is essential before crafting any outreach strategy: the vast majority of MMRF's grant dollars — roughly 91% of the $57.26M recorded across 49 grants in available data — flow internally to three affiliated entities: Michelson Found Animals Foundation ($32.5M over five grants), Michelson 20mm Foundation ($10.5M over five grants), and Michelson Philanthropies Inc. ($9.05M over three grants). These are programmatic arms, not independent organizations competing in open solicitations.

For external applicants, the only competitive open pathway is the Michelson Prizes: Next Generation Grants — $150,000 awards given annually to early-career scientists advancing human immunology, vaccine discovery, and immunotherapy. This program is administered by Next Frontier Advisors, a third-party firm, which shapes the formal application experience and should be the first point of contact for process questions.

MMRF's giving philosophy, articulated directly by founder Dr. Michelson, centers on supporting 'high-risk, high-reward' science with potential to affect 'the lives of billions.' The foundation explicitly courts disruptive concepts over incremental research, evidenced by its institutional partnerships with the USC Michelson Center for Convergent Bioscience and a $120M commitment to establish UCLA's California Institute for Immunology & Immunotherapy (CIII). First-time applicants should understand that MMRF favors research that removes systemic barriers to vaccine and immunotherapy development — not isolated findings within established paradigms.

There is no LOI stage or multi-step proposal process for the Next Gen Grants: applicants submit directly through the smapply.io portal within a narrow annual window (April through late June). Beyond the Next Gen Grants, MMRF's larger strategic investments originate through Dr. Michelson's direct academic relationships, not through open solicitations. Organizations seeking seven- or eight-figure partnerships should prioritize building credibility in the immunology field and pursuing introductions through MMRF's academic partner network — particularly USC and UCLA — rather than submitting unsolicited proposals.

MMRF's annual giving has remained remarkably consistent over the past decade: $11.95M (FY2021), $12.27M in total giving (FY2022), $12.49M in grants paid (FY2023), and a range of $11.5M–$13.7M throughout 2019–2023. This consistency reflects disciplined, pre-planned grantmaking rather than opportunistic deployment. Total assets stood at $250.75M as of FY2024 (down from $268.1M in FY2023), generating approximately $9.65M in net investment income in FY2023 and $17.4M in total revenue in FY2024. The foundation classifies itself as a non-operating private foundation (foundation code 04).

The grant distribution is highly concentrated: three affiliated Michelson entities received $52.05M of $57.26M total recorded giving — leaving approximately $5.2M distributed externally across 14+ independent organizations over the same multi-year period. The raw average grant across all 49 recorded grants is $1.17M, but this figure is distorted by the large affiliate transfers. For external grantees, the practical range runs from $2,500 (Latino Medical Student Association) to $2.165M (Milken Institute), with a median of approximately $61,600.

For the competitive Next Gen Grants program specifically: five $150,000 awards per year = $750,000 annually. The 2024 cycle issued three awards ($450,000 total); the 2026 cycle expanded to five awards — a meaningful 67% increase in slots and dollars.

Geographically, California dominates: 34 of 49 grant records (69%) are California-based, consistent with MMRF's Los Angeles headquarters and its ties to USC and UCLA. New York accounts for 9 grants (18%), DC for 4 (8%), and Colorado for 2 (4%). The 2026 Next Gen cohort extended to Sweden (Lund University), indicating international applicants are competitive.

By program area (dollar value): animal welfare via Found Animals represents approximately 57% of total recorded giving, education via 20mm Foundation 18%, philanthropic coordination via Philanthropies 16%, and all external medical and immunology-related grants combined represent roughly 9%. Applicants competing for Next Gen Grants are accessing a $750K annual pool — a strategically important but numerically modest slice of MMRF's total annual deployment of $12–13M.

The following table compares MMRF to four peer foundations at similar asset levels in the Philanthropy & Grantmaking category:

Among similarly-sized private foundations in the $250M asset band, MMRF stands out for operating a publicly competitive, structured grant program — an uncommon feature at this scale, where most peers operate by invitation only or focus on community development and private grantmaking without an open application pathway. MMRF's specialized medical research mandate, its cross-disciplinary academic ecosystem (USC, UCLA), and its annual public prize cycle give it a distinctive profile: it functions simultaneously as a family foundation channeling resources to affiliated entities and as an active supporter of external scientific innovation. Grant seekers in the immunology and biomedical fields have access to an open competitive door at MMRF that simply does not exist at most comparably endowed foundations.

In February 2026, MMRF announced its eighth cohort of Next Generation Grant recipients — the largest-ever at five scientists, totaling $750,000. Recipients included Dr. Theodore Roth (Stanford University, CRISPR-based immune reprogramming), Dr. Mohamad Abedi (University of Washington, AI-designed synthetic cytokines), Dr. Inta Gribonika (Lund University, Sweden, skin immunity and tertiary lymphoid organs), Dr. Joshua Gray (Columbia University, infant mucosal immunity), and Dr. Benjamin Morehouse (University of California Irvine, immune enzyme function in innate immunity). Founder Dr. Gary Michelson explicitly linked the cohort expansion to declining federal research funding, stating the foundation was responding to 'a surge in exceptional applications.' This framing signals that MMRF may sustain or grow its competitive grant volume in response to NIH and NSF budget pressures in the coming cycles.

The 2026/2027 application portal was announced to open March 30, 2026, continuing MMRF's annual spring-to-summer cycle. In 2024, MMRF awarded $150,000 each to three scientists: Dr. Omar Abudayyeh (RNA therapies), Dr. Caleb Lareau (human virome research), and Dr. Yuzhong Liu (vaccine adjuvants). No leadership changes were identified: Dr. Gary Michelson remains President and Director, David Cohen serves as Secretary/CFO, and Michele Morris is Program Manager. The Michelsons' $120M UCLA CIII commitment remains the most significant long-term institutional investment in the foundation's recent history.

The Next Generation Grants program is the primary — and essentially the only — open competitive opportunity at MMRF. Applicants must treat it with corresponding rigor.

Confirm hard eligibility first. The age ceiling of 35 is strictly enforced; no published waiver process exists. Confirm your eligibility before investing time in application materials. Research must focus on human immunology, vaccine discovery, or immunotherapy — animal-only models without clear human immune system relevance will not qualify.

Use MMRF's exact language in your proposal. The foundation's published framing consistently emphasizes 'disruptive,' 'high-risk, high-reward,' and 'paradigm-challenging' science. Reviewers score against these criteria explicitly. Do not frame your work as confirmatory, incremental, or translating an established finding — position it as removing a specific barrier or overturning a received assumption in the field.

Lean into interdisciplinary framing. MMRF's own portfolio — from the USC convergent bioscience center to the UCLA CIII — demonstrates deep commitment to cross-disciplinary approaches. Researchers in AI/machine learning, computational biology, protein engineering, biophysics, or nanotechnology should explicitly articulate how their methods unlock immunological insights unavailable through conventional approaches. The 2026 cohort included AI-driven protein design (Abedi) and CRISPR engineering (Roth) — both non-traditional immunology approaches.

International applicants are genuinely competitive. Lund University's Dr. Gribonika won in 2026 despite being based in Sweden. Do not assume U.S. institutional affiliation is required.

Optimize your timing. The 2025 cycle ran April 1 – June 22 and the 2026/2027 portal opens March 30, 2026. Submit at least one week before the June deadline to allow for platform troubleshooting on smapply.io. Download and review both the application preview PDF and the program structure PDF from the grants page before opening the portal — these documents reveal the exact form structure and required sections.

Route all questions to the administrator. Email michelsonprizes@nextfrontieradvisors.com for eligibility and process questions. MMRF uses Next Frontier Advisors as its program intermediary; contacting MMRF staff directly about Next Gen Grants will likely result in redirections that cost time.